Product Description
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Brazil | Colombia | Dominican Republic | Egypt | Germany | Hungary | India | Indonesia | Italy | Jordan | Korea | Lebanon | Malaysia | Mexico | Pakistan | Peru | Philippines | Portugal | South Africa | Spain | Taiwan | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Kuopio University Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acne Vulgaris|Pressure Ulcer|Chronic Pain|Labor Pain|Environmental Hypersensitivity|Acute Pain